# Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 > Briefs, arguments, decisions, and more. URL: https://www.frixlaw.com/law-library/documents/fr%3A2021-24921 ## Record - **Collection:** Federal Register - **Document type:** Notice - **Published:** November 15, 2021 - **Citation:** 86 FR 63061 ## Text DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-688F] Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final order. SUMMARY: This final order establishes the final adjusted 2021 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. DATES: This order is effective November 15, 2021. FOR FURTHER INFORMATION CONTACT: Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362-3261. SUPPLEMENTARY INFORMATION: Legal Authority Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100. Background DEA published the 2021 established APQ for controlled substances in schedules I and II and for the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the Federal Register on November 30, 2020. 85 FR 76604. DEA is committed to preventing and limiting diversion by enforcing laws and regulations regarding controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the legitimate medical, scientific, and export needs of the United States. This notice stated that the Administrator would adjust, as needed, the established APQ in 2021 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. The 2021 proposed adjusted APQ for controlled substances in schedules I and II and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the Federal Register on September 2, 2021, (86 FR 49346), after consideration of the criteria outlined in that notice. All interested persons were invited to comment on or object to the proposed APQs and AANs on or before October 4, 2021. Comments Received DEA received 27 timely comments in response to the September Federal Register notice from patients, DEA-registered entities, and non-DEA entities. The comments included appreciation of DEA's response to the increased interest in research using hallucinogenic controlled substances, requests to increase the APQ for additional hallucinogenic controlled substances, requests to increase the APQ for select schedule II controlled substances, concerns regarding the inability to comment to the notice electronically for two weeks, and comments outside the scope of this final order. Issue: Commenters expressed appreciation of DEA's flexibility in responding to the nationwide public interest in hallucinogenic controlled substances research. DEA Response: DEA acknowledges the expressions of appreciation to changes in the APQ for these controlled substances. The adjustments to select hallucinogenic schedule I controlled substances occurred after DEA received additional schedule I researcher protocols from DEA registered researchers and quota applications from DEA registered manufacturers. Issue: Commenters requested DEA to increase the APQ for Bufotenine, Dimethyltryptamine (DMT), N,N-Dimethyltryptamine, 5-Methoxy-N,N- dimethyltryptamine (5MEODMT), Ibogaine, Ketamine, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Mescaline, Mitragynine, and Psilocybin in response to the nationwide public interest in hallucinogenic controlled substances research. DEA Response: Ketamine is a schedule III controlled substance and therefore is outside of the scope of this final order as DEA only sets APQs for substances controlled in schedules I and II. DEA received additional quota applications for DMT, MDMA, and Psilocybin and considered the timely provided information in those applications for this final order. Regarding the other controlled substances listed, DEA has not received quota applications from DEA-registered manufacturers to support the requested changes in the APQ for these controlled substances. Mitragynine is not a controlled substance and therefore is outside the scope of this final order. Issue: DEA-registered entities requested that the APQ for Methadone, Methadone Intermediate, Methylphenidate Oxycodone (for sale), Phenylacetone, and Thebaine be sufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks. DEA Response: DEA sets APQ in a manner to ensure that the estimated medical, scientific, research, industrial needs of the United States, lawful export requirements, and for the establishment and maintenance of reserve stocks. As discussed in the notice for adjustment, any adjustments to the APQ for a controlled substance are based on factors set forth in 21 CFR 1303.13. In the event of a shortage, the CSA provides a mechanism under which DEA will, in appropriate circumstances, increase quotas to address shortages. 21 U.S.C. 826(h). Under 21 U.S.C. 826(h)(1), after receiving a request to address a shortage, DEA has 30 days to complete review of the request and determine whether adjustments are necessary to address the shortage. If adjustments are necessary, DEA is required to increase the APQ and individual production quotas to alleviate the shortage. Id. If DEA determines adjustments are not necessary, DEA is required to “provide a written response detailing the basis for the . . . determination.” Id. In addition to what Section 826(h)(1) requires, when DEA is notified of an alleged shortage, DEA will confer with the Food and Drug Administration and relevant manufacturers regarding the amount of material in physical inventory, current quota granted, and the estimated legitimate medical need, to determine whether a quota adjustment is necessary to alleviate any quota-related drug shortage. In accordance with 21 CFR 1303.13, DEA considered the comments for Bufotenine, 5-Methoxy-N,N-dimethyltryptamine (5MEODMT), Ibogaine, Lysergic Acid Diethylamide (LSD), Mescaline, Methadone, Methadone Intermediate, Oxycodone (for sale), and Thebaine and the Administrator determined the proposed adjusted 2021 APQs for these substances as published in the Federal Register on September 2, 2021, (86 FR 49346), are sufficient to meet the current 2021 estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and to provide for adequate reserve stock. Issue: Commenters expressed general concerns regarding the inability to submit electronic comments to the notice published on September 2, 2021, for two weeks. Commenters requested an extension of the comment period to allow for additional comments. DEA Response: DEA acknowledges that commenters could not submit electronic comments to the notice for two weeks. However, written comments could be submitted via mail to the address provided in the notice. Written comments that were postmarked on or before October 4, 2021, were considered in this final order. DEA notes that one commenter submitted identical electronic and written comments both of which were timely postmarked, received, and considered for this final order. Out of Scope Comments: DEA received comments on issues outside the scope of this final order. Commenters made several suggestions to the DEA, including: (1) Seeking assistance from indigenous communities to determine the amount of psychedelic substances that would be needed to conduct research; (2) making the United States a signatory to the Nagoya Protocol and the Convention on Biological Diversity; and (3) creating diversified categories for production and research on psilocybin-containing fungi fruiting bodies/sclerotia/liquid culture similar to cannabis (flower), fruiting body extract (akin to cannabis extract), and psilocybin and psilocin separately as purified compounds (akin to delta-9-thc). Regarding this last suggestion, the commenter further suggested that the “same system should then be replicated in regards to lophophora/mescaline, as well as other plants, fungi and lifeforms, which produce these compounds being used in whole or closer to whole ways.” DEA received other comments that were general in nature and raised issues of specific medical illnesses and medical treatments. All of the issues raised are outside of the scope of this final order for 2021 and do not impact the original analysis involved in finalizing the 2021 APQ. Analysis for Final Adjusted 2021 Aggregate Production Quotas and Assessment of Annual Needs In determining the final adjusted 2021 APQ and AAN, DEA considered the above comments relevant to this final order for calendar year 2021, along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13, in accordance with 21 U.S.C. 826(a). DEA has also considered other relevant factors, including the 2020 year-end inventories, initial 2021 manufacturing and import quotas, 2021 export requirements, actual and projected 2021 sales, research and product development requirements, additional applications received, and the extent of any diversion of the controlled substance in the class. Based on all of the above, the Administrator is adjusting the 2021 APQ for the following: 3,4-Methylenedioxymethamphetamine (MDMA), 4,4′-Dimethylaminorex, Dimethyltryptamine (DMT), Lisdexamfetamine, Methiopropamine, Psilocybin, Psilocyn, and Phenylacetone. This final order reflects those adjustments. Pursuant to the above, the Administrator hereby finalizes the 2021 APQ for the following schedule I and II controlled substances and the 2021 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Basic class Final adjusted 2021 quotas (g) Schedule I 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 20 1-(1-Phenylcyclohexyl)pyrrolidine 30 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 10 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 30 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 30 1-Benzylpiperazine 25 1-Methyl-4-phenyl-4-propionoxypiperidine 10 1-[1-(2-Thienyl)cyclohexyl]piperidine 15 2'-fluoro 2-fluorofentanyl 30 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) 30 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 100 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 30 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 30 2,5-Dimethoxy-4-ethylamphetamine (DOET) 25 2,5-Dimethoxy-4-n-propylthiophenethylamine 25 2,5-Dimethoxyamphetamine (DMA) 25 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 30 3,4,5-Trimethoxyamphetamine 30 3,4-Methylenedioxyamphetamine (MDA) 55 3,4-Methylenedioxymethamphetamine (MDMA) 3,200 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 40 3,4-Methylenedioxy-N-methylcathinone (methylone) 40 3,4-Methylenedioxypyrovalerone (MDPV) 35 3-FMC; 3-Fluoro-N-methylcathinone 25 3-Methylfentanyl 30 3-Methylthiofentanyl 30 4′-Methyl acetyl fentanyl 30 4,4'-Dimethylaminorex 30 4-Bromo-2,5-dimethoxyamphetamine (DOB) 30 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 25 4-Chloro-α-pyrrolidinovalerophenone (4-chloro-alpha-PVP) 25 4CN-Cumyl-Butanica, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide 25 4F-MDMB-BINACA 30 4-Fluoroisobutyryl fentanyl 30 4-FMC; Flephedrone 25 4-MEC; 4-Methyl-N-ethylcathinone 25 4-Methoxyamphetamine 150 4-Methyl-2,5-dimethoxyamphetamine (DOM) 25 4-Methylaminorex 25 4-Methyl-N-methylcathinone (mephedrone) 45 4-Methyl-α-ethylaminopentiophenone (4-MEAP) 25 4-Methyl-α-pyrrolidinohexiophenone (MPHP) 25 4-Methyl-α-pyrrolidinopropiophenone (4-MePPP) 25 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 50 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40 5F-CUMYL-PINACA 25 5F-EDMB-PINACA 25 5F-MDMB-PICA 25 5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 25 5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide) 25 5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 30 5F-AMB (methyl 2-(1-(5-fluoropentyl)-1 H -indazole-3-carboxamido)-3-methylbutanoate) 30 5F-APINACA; 5F-AKB48 ( N -(adamantan-1-yl)-1-(5-fluoropentyl)-1 H -indazole-3-carboxamide) 30 5-Fluoro-PB-22; 5F-PB-22 20 5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1 H- indol- 3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 25 5-Methoxy-3,4-methylenedioxyamphetamine 25 5-Methoxy-N,N-diisopropyltryptamine 25 5-Methoxy-N,N-dimethyltryptamine 35 AB-CHMINACA 30 AB-FUBINACA 50 AB-PINACA 30 ADB-FUBINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide) 30 Acetorphine 25 Acetyl Fentanyl 100 Acetyl- alpha -methylfentanyl 30 Acetyldihydrocodeine 30 Acetylmethadol 25 Acryl Fentanyl 25 ADB-PINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide) 50 AH-7921 30 All other tetrahydrocannabinol 1,000 Allylprodine 25 Alphacetylmethadol 25 alpha- Ethyltryptamine 25 Alphameprodine 25 Alphamethadol 25 Alphaprodine 25 alpha -Methylfentanyl 30 alpha -Methylthiofentanyl 30 alpha -Methyltryptamine (AMT) 25 alpha -Pyrrolidinobutiophenone (α-PBP) 25 alpha -Pyrrolidinoheptaphenone (PV8) 25 alpha- Pyrrolidinohexanophenone (α-PHP) 25 alpha -Pyrrolidinopentiophenone (α-PVP) 25 Aminorex 25 Anileridine 20 APINCA, AKB48 ( N -(1-adamantyl)-1-pentyl-1 H -indazole-3-carboxamide) 25 Benzethidine 25 Benzylmorphine 30 Betacetylmethadol 25 beta -Hydroxy-3-methylfentanyl 30 beta -Hydroxyfentanyl 30 beta -Hydroxythiofentanyl 30 beta -Methyl fentanyl 30 beta -Phenyl fentanyl 30 Betameprodine 25 Betamethadol 4 Betaprodine 25 Brorphine 30 Bufotenine 15 Butylone 25 Butyryl fentanyl 30 Cathinone 40 Clonitazene 25 Codeine methylbromide 30 Codeine-N-oxide 192 Cyclopentyl Fentanyl 30 Cyclopropyl Fentanyl 20 Cyprenorphine 25 d-9-THC 384,460 Desomorphine 25 Dextromoramide 25 Diapromide 20 Diethylthiambutene 20 Diethyltryptamine 25 Difenoxin 9,200 Dihydromorphine 753,500 Dimenoxadol 25 Dimepheptanol 25 Dimethylthiambutene 20 Dimethyltryptamine 3,200 Dioxyaphetyl butyrate 25 Dipipanone 25 Drotebanol 25 Ethylmethylthiambutene 25 Etorphine 30 Etoxeridine 25 Fenethylline 30 Fentanyl carbamate 30 Fentanyl related substances 600 FUB-144 25 FUB-AKB48 25 FUB-AMB, MMB-Fubinaca, AMB-Fubinaca 25 Furanyl fentanyl 30 Furethidine 25 gamma -Hydroxybutyric acid 29,417,000 Heroin 45 Hydromorphinol 40 Hydroxypethidine 25 Ibogaine 30 Isobutyryl Fentanyl 25 JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 JWH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) 30 JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) 35 JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) 30 JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) 30 JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) 30 Ketobemidone 30 Levomoramide 25 Levophenacylmorphan 25 Lysergic acid diethylamide (LSD) 40 MAB-CHMINACA; ADB-CHMINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide) 30 MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1 H -indole-3-carboxamido)-3,3-dimethylbutanoate) 30 MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1 H -indazole-3-carboxamido)-3,3-dimethylbutanoate) 30 MMB-CHMICA-(AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate 25 Marihuana 2,000,000 Marihuana extract 500,000 Mecloqualone 30 Mescaline 25 Methaqualone 60 Methcathinone 25 Methiopropamine 30 Methyoxyacetyl fentanyl 30 Methyldesorphine 5 Methyldihydromorphine 25 Morpheridine 25 Morphine methylbromide 5 Morphine methylsulfonate 5 Morphine-N-oxide 150 MT-45 30 Myrophine 25 NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 25 N,N -Dimethylamphetamine 25 Naphyrone 25 N -Ethyl-1-phenylcyclohexylamine 25 N -Ethyl-3-piperidyl benzilate 10 N -Ethylamphetamine 24 N- Ethylhexedrone 25 N- Ethylpentylone, ephylone 30 N -Hydroxy-3,4-methylenedioxyamphetamine 24 N-Methyl-3-Piperidyl Benzilate 30 Nicocodeine 25 Nicomorphine 25 Noracymethadol 25 Norlevorphanol 2,550 Normethadone 25 Normorphine 40 Norpipanone 25 Ocfentanil 25 Ortho-fluorofentanyl, 2-fluorofentanyl 30 ortho -Fluoroacryl fentanyl 30 ortho -Fluorobutyryl fentanyl 30 ortho -Fluoroisobutyryl fentanyl 30 ortho -Methyl acetylfentanyl 30 ortho -Methyl methoxyacetyl fentanyl 30 Para-chloroisobutyryl fentanyl 30 Para-fluorofentanyl 25 Para-fluorobutyryl fentanyl 25 para -Fluoro furanyl fentanyl 30 para -Methylfentanyl 30 Para-methoxybutyryl fentanyl 30 Parahexyl 5 PB-22; QUPIC 20 Pentedrone 25 Pentylone 25 Phenadoxone 25 Phenampromide 25 Phenomorphan 25 Phenoperidine 25 Phenyl fentanyl 30 Pholcodine 5 Piritramide 25 Proheptazine 25 Properidine 25 Propiram 25 Psilocybin 6,000 Psilocyn 3,500 Racemoramide 25 SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) 45 SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30 Tetrahydrofuranyl fentanyl 15 Thebacon 25 Thiafentanil 25 Thiofentanyl 25 Thiofuranyl fentanyl 30 THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) 30 Tilidine 25 Trimeperidine 25 UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 25 U-47700 30 Valeryl fentanyl 25 Schedule II 1-Phenylcyclohexylamine 15 1-Piperidinocyclohexanecarbonitrile 25 4-Anilino-N-phenethyl-4-piperidine (ANPP) 937,758 Alfentanil 3,260 Alphaprodine 25 Amobarbital 20,100 Bezitramide 25 Carfentanil 20 Cocaine 68,576 Codeine (for conversion) 1,612,500 Codeine (for sale) 27,616,684 D-amphetamine (for sale) 21,200,000 D,l-amphetamine 21,200,000 D-amphetamine (for conversion) 16,068,789 Dextropropoxyphene 35 Dihydrocodeine 156,713 Dihydroetorphine 25 Diphenoxylate (for conversion) 14,100 Diphenoxylate (for sale) 770,800 Ecgonine 68,576 Ethylmorphine 30 Etorphine hydrochloride 32 Fentanyl 731,452 Glutethimide 25 Hydrocodone (for conversion) 1,250 Hydrocodone (for sale) 30,821,224 Hydromorphone 2,743,101 Isomethadone 30 L-amphetamine 30 Levo-alphacetylmethadol (LAAM) 25 Levomethorphan 30 Levorphanol 26,495 Lisdexamfetamine 22,500,000 L-methamphetamine 587,229 Meperidine 856,695 Meperidine Intermediate-A 30 Meperidine Intermediate-B 30 Meperidine Intermediate-C 30 Metazocine 15 Methadone (for sale) 25,619,700 Methadone Intermediate 27,673,600 Methamphetamine 50 D-methamphetamine (for conversion) 485,020 D-methamphetamine (for sale) 40,000 Methylphenidate (for conversion) 15,300,000 Methylphenidate (for sale) 57,438,334 Metopon 25 Moramide-intermediate 25 Morphine (for conversion) 3,376,696 Morphine (for sale) 26,505,995 Nabilone 62,000 Norfentanyl 25 Noroxymorphone (for conversion) 22,044,741 Noroxymorphone (for sale) 376,000 Oliceridine 22,500 Opium (powder) 250,000 Opium (tincture) 530,837 Oripavine 33,010,750 Oxycodone (for conversion) 620,887 Oxycodone (for sale) 57,110,032 Oxymorphone (for conversion) 28,204,371 Oxymorphone (for sale) 563,174 Pentobarbital 30,766,670 Phenazocine 25 Phencyclidine 35 Phenmetrazine 25 Phenylacetone 6,100,000 Piminodine 25 Racemethorphan 5 Racemorphan 5 Remifentanil 3,000 Secobarbital 172,100 Sufentanil 4,000 Tapentadol 13,447,541 Thebaine 57,137,944 List I Chemicals Ephedrine (for conversion) 100 Ephedrine (for sale) 4,136,000 Phenylpropanolamine (for conversion) 14,878,320 Phenylpropanolamine (for sale) 16,690,000 Pseudoephedrine (for conversion) 1,000 Pseudoephedrine (for sale) 174,246,000 The Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Anne Milgram, Administrator. [FR Doc. 2021-24921 Filed 11-10-21; 4:15 pm] BILLING CODE 4410-09-P --- Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A2021-24921. Public record. Not legal advice.